MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Evaluation of a double-target therapeutic in preclinical models of Parkinson’s disease

FJ. Sanz, C. Solana-Manrique, E. Masià, MJ. Vicent, N. Paricio (Burjassot, Spain)

Meeting: MDS Virtual Congress 2021

Abstract Number: 532

Keywords: DJ-1 mutation, Parkinson’s, Pharmacotherapy

Category: Parkinson’s Disease: Pharmacology and Therapy

Objective: To evaluate the effectiveness of a candidate compound identified in a high-throughput screening (HTS) assay carried out in a Drosophila model of Parkinson’s disease (PD) and validated in neuron-like human cells as PD cell model.

Background: There is no cure for PD, and current therapies are mainly addressed to relieve motor symptoms. However, they are not able to stop, delay or counteract the PD progression. To identify new therapeutic drugs, we carried out a HTS assay testing compounds from the Prestwick Chemical Library (1120 compounds) in a fly PD model based on DJ-1 deficiency, a causative gene of familial PD highly related to sporadic cases of the disease. Among the compounds able to suppress locomotor defects in PD model flies that were also shown to reduce oxidative stress (OS)-induced lethality in PD model cells, we focused on compound 118 (C118) since it was the most effective in DJ-1-deficient cells. Interestingly, one of its targets has never been proposed for therapeutic intervention in PD.

Method: We analyzed protein carbonylation levels using 2,4-dinitrophenylhydrazine and H2O2 levels using the commercial kit Amplex Red in extracts of 5-day-old treated PD model flies. Subsequently, we established the optimal dose of C118 by carrying out an MTT viability assay in DJ-1 mutant cells. Next, western-blots were performed to study Akt and JNK phosphorylation (anti-apoptotic and pro-apoptotic factors respectively) in C118 treated PD cells. Mitochondrial viability of cells was studied using the fluorescence dye MitoTracker. The glycolytic rate in treated cells was tested by quantifying the activity of key enzymes of this pathway.

Results: We found that C118 was able to reduce H2O2 and protein carbonylation levels in 5-day-old DJ-1β mutant flies. C118 exerted a neuroprotective effect in PD model cells by activating Akt and inhibiting JNK signaling. In addition, C118 was also able to increase mitochondrial viability and to enhance the glycolytic pathway in DJ-1-silenced cells.

Conclusion: In this work, we have demonstrated the effectiveness of C118 in suppressing PD-related phenotypes in preclinical models of the disease. In addition, C118 is able to increase the glycolytic rate, a strategy that has been recently proposed as a promising therapeutic target in PD. Interestingly, this compound presents two different targets with interest in PD treatment, hence widening the therapeutic landscape.

To cite this abstract in AMA style:

FJ. Sanz, C. Solana-Manrique, E. Masià, MJ. Vicent, N. Paricio. Evaluation of a double-target therapeutic in preclinical models of Parkinson’s disease [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/evaluation-of-a-double-target-therapeutic-in-preclinical-models-of-parkinsons-disease/. Accessed July 6, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to MDS Virtual Congress 2021

MDS Abstracts - https://www.mdsabstracts.org/abstract/evaluation-of-a-double-target-therapeutic-in-preclinical-models-of-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley